DOJ Moves Certain Marijuana Products to Schedule III, Sets June Rescheduling Hearing

Why It Matters

Reclassifying medical cannabis to Schedule III eases federal‑state tension and could pave the way for wider legalization, while forcing employers to adjust compliance and accommodation policies.

Key Takeaways

• DOJ places FDA‑approved and state‑licensed medical cannabis in Schedule III
• Unlicensed marijuana and bulk extracts stay in Schedule I
• June 29 hearing will decide broader rescheduling of cannabis
• Employers must treat medical cannabis like other prescription drugs under ADA
• DOT drug‑testing rules still target Schedule I/II until updated

Pulse Analysis

The Department of Justice’s decision to move FDA‑approved and state‑licensed medical marijuana products into Schedule III marks the most significant federal policy shift since cannabis was first placed in Schedule I in 1970. Schedule III classification signals that these products have recognized medical use and a lower abuse potential, aligning federal law with the growing number of state medical programs. By creating an expedited registration process for state‑licensed growers and manufacturers, the order streamlines the path to federal compliance, potentially unlocking new investment and research opportunities in the burgeoning cannabinoid sector.

For the cannabis industry, the partial rescheduling offers both clarity and new challenges. Companies that already hold FDA approvals—such as Epidiolex, Marinol, Syndros, and Cesamet—can now market under a federal schedule that permits prescription use, reducing legal risk and facilitating insurance reimbursement. However, the bulk of the market—unlicensed flower, extracts, and recreational products—remains in Schedule I, preserving the current regulatory divide. This bifurcation may spur consolidation as firms seek FDA pathways or state licenses to gain federal legitimacy, while also prompting lobbying efforts ahead of the June 29 hearing that could reshape the entire schedule hierarchy.

Employers are the immediate downstream audience of the schedule change. Under the Americans with Disabilities Act, medical marijuana use must be evaluated like any other prescription medication, requiring interactive processes and direct‑threat analyses for safety‑sensitive roles. Yet the Department of Transportation continues to restrict testing to Schedule I and II substances, meaning DOT‑regulated employers must maintain existing testing protocols until the agency updates its guidance. The dual landscape of federal scheduling and state recreational laws creates a complex compliance matrix, urging HR and legal teams to stay vigilant as the June hearing outcomes could further alter drug‑testing standards and workplace accommodations.